CoChat
Sign Up
Cited by 119COVID-19 Clinical Research StudiesRespiratory Support and MechanismsSepsis Diagnosis and Treatment

The DOI matches its Crossref record; 18 of the 19 references it cites were found in a registry or an index.

Anakinra treatment in critically ill COVID-19 patients: a prospective cohort study

Open access
the RCI-COVID-19 Study Group, Kooistra, Emma J., Waalders, Nicole J. B., Grondman, Inge, Janssen, Nico A. F., de Nooijer, Aline H., Netea, Mihai G., van de Veerdonk, Frank L., Ewalds, Esther, van der Hoeven, Johannes G., Kox, Matthijs, Pickkers, Peter·2020·Critical Care
DOI 10.1186/s13054-020-03364-wPMC PMC7726611
Open this paper in CoChat — free accountOpen PDF

Abstract

Background: A subset of critically ill COVID-19 patients develop a hyperinflammatory state. Anakinra, a recombinant interleukin-1 receptor antagonist, is known to be effective in several hyperinflammatory diseases. We investigated the effects of anakinra on inflammatory parameters and clinical outcomes in critically ill, mechanically ventilated COVID-19 patients with clinical features of hyperinflammation. Methods: In this prospective cohort study, 21 critically ill COVID-19 patients treated with anakinra were compared to a group of standard care. Serial data of clinical inflammatory parameters and concentrations of multiple circulating cytokines were determined and aligned on start day of anakinra in the treatment group, and median start day of anakinra in the control group. Analysis was performed for day − 10 to + 10 relative to alignment day. Clinical outcomes were analyzed during 28 days. Additionally, three sensitivity analyses were performed: (1) using propensity score-matched groups, (2) selecting patients who did not receive corticosteroids, and (3) using a subset of the control group aimed to match the criteria (fever, elevated ferritin) for starting anakinra treatment. Results: Baseline patient characteristics and clinical parameters on ICU admission were similar between groups. As a consequence of bias by indication, plasma levels of aspartate aminotransferase (ASAT) (p = 0.0002), ferritin (p = 0.009), and temperature (p = 0.001) were significantly higher in the anakinra group on alignment day. Following treatment, no relevant differences in kinetics of circulating cytokines were observed between both groups. Decreases of clinical parameters, including temperature (p = 0.03), white blood cell counts (p = 0.02), and plasma levels of ferritin (p = 0.003), procalcitonin (p = 0.001), creatinine (p = 0.01), and bilirubin (p = 0.007), were more pronounced in the anakinra group. No differences in duration of mechanical ventilation or ICU length of stay were observed between groups. Sensitivity analyses confirmed these results. Conclusions: Anakinra is effective in reducing clinical signs of hyperinflammation in critically ill COVID-19 patients. A randomized controlled trial is warranted to draw conclusion about the effects of anakinra on clinical outcomes.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1186/s13054-020-03364-w

Cites

18 of 18 references verified0 citation errors · 0 not checkable

Statistics

Figures

Fig. 1 Circulating cytokine concentrations. Concentrations of circulating a tumor necrosis factor (TNF)-α, b interleukin (IL)-6, c IL-8, d IL-10, e interferon gamma-induced protein (IP)-10, f monocyte chemoattractant protein (MCP)-1, and g IL-1 receptor antagonist (IL-1RA) on day of intensive care unit (ICU) admission and serial data within six days pre- and post-alignment day (day 0). Data are presented as geometric mean with 95% confidence intervals and were analyzed using mixed-models analysis (time*group interaction factor) to evaluate differences between groups over time. p values under graph titles reflect overall between-group differences (day − 6 until day 6). Between-group p values for day − 6 until day 0 and day 0 until day 6 are shown on the left and right of each panel, respectively
Fig. 1 Circulating cytokine concentrations. Concentrations of circulating a tumor necrosis factor (TNF)-α, b interleukin (IL)-6, c IL-8, d IL-10, e interferon gamma-induced protein (IP)-10, f monocyte chemoattractant protein (MCP)-1, and g IL-1 receptor antagonist (IL-1RA) on day of intensive care unit (ICU) admission and serial data within six days pre- and post-alignment day (day 0). Data are presented as geometric mean with 95% confidence intervals and were analyzed using mixed-models analysis (time*group interaction factor) to evaluate differences between groups over time. p values under graph titles reflect overall between-group differences (day − 6 until day 6). Between-group p values for day − 6 until day 0 and day 0 until day 6 are shown on the left and right of each panel, respectivelyCC BY · PubMed Central
Fig. 2 Proteomics inflammation panel and kinetics of inflammatory parameters. a Volcano plot of proteomics inflammation panel for 75 proteins in both groups. Mean fold change and − 10log(p value) were shown on the x-axis and y-axis, respectively. p values were calculated using t tests. A mean fold change of ≤ -2 or ≥ 2 was considered relevant. A − 10log(p value) > 3.204 was considered significant (p < 0.000625). b Body temperature and plasma levels of c ferritin, d procalcitonin, e white blood cell counts, and f C-reactive protein (CRP) over time within 10 days pre- and post-start anakinra alignment day (day 0). Data are presented as geometric mean with 95% confidence intervals and were analyzed using mixed-models analysis (time*group interaction factor) to evaluate differences between groups over time. p values under graph titles reflect overall between-group differences (day − 10 until day 10). Between-group p values for day − 10 until day 0 and day 0 until day 10 are shown on the left and right of each panel, respectively
Fig. 2 Proteomics inflammation panel and kinetics of inflammatory parameters. a Volcano plot of proteomics inflammation panel for 75 proteins in both groups. Mean fold change and − 10log(p value) were shown on the x-axis and y-axis, respectively. p values were calculated using t tests. A mean fold change of ≤ -2 or ≥ 2 was considered relevant. A − 10log(p value) > 3.204 was considered significant (p < 0.000625). b Body temperature and plasma levels of c ferritin, d procalcitonin, e white blood cell counts, and f C-reactive protein (CRP) over time within 10 days pre- and post-start anakinra alignment day (day 0). Data are presented as geometric mean with 95% confidence intervals and were analyzed using mixed-models analysis (time*group interaction factor) to evaluate differences between groups over time. p values under graph titles reflect overall between-group differences (day − 10 until day 10). Between-group p values for day − 10 until day 0 and day 0 until day 10 are shown on the left and right of each panel, respectivelyCC BY · PubMed Central
Fig. 3 Individual parameters of sequential organ failure assessment (SOFA) score and total SOFA score. Plasma levels of a creatinine, b bilirubin, and c thrombocytes and d PaO2/FiO2 (P/F) ratio, e infusion rate of norepinephrine, and f SOFA score over time within 10 days pre- and post-alignment day (day 0). PaO2/FiO2 ratio and SOFA score were presented until day 6. Data are presented as geometric mean with 95% confidence intervals and were analyzed using mixed-models analysis (time*group interaction factor) to evaluate differences between groups over time. p values under graph titles reflect overall between-group differences (day − 10 until day 6 or 10). Between-group p values for day − 10 until day 0 and day 0 until day 6 or 10 are shown on the left and right of each panel, respectively
Fig. 3 Individual parameters of sequential organ failure assessment (SOFA) score and total SOFA score. Plasma levels of a creatinine, b bilirubin, and c thrombocytes and d PaO2/FiO2 (P/F) ratio, e infusion rate of norepinephrine, and f SOFA score over time within 10 days pre- and post-alignment day (day 0). PaO2/FiO2 ratio and SOFA score were presented until day 6. Data are presented as geometric mean with 95% confidence intervals and were analyzed using mixed-models analysis (time*group interaction factor) to evaluate differences between groups over time. p values under graph titles reflect overall between-group differences (day − 10 until day 6 or 10). Between-group p values for day − 10 until day 0 and day 0 until day 6 or 10 are shown on the left and right of each panel, respectivelyCC BY · PubMed Central
Fig. 4 Clinical outcomes. Kaplan–Meier graphs of a time on mechanical ventilator, b length of stay in the intensive care unit (ICU), and c mortality. Data are presented for the first 28 days after anakinra alignment day. Patients who were no longer mechanically ventilated on alignment day were not included in time on ventilator graph. p values were calculated using log-rank tests. Numbers at risk on each timepoint per group are shown below graphs
Fig. 4 Clinical outcomes. Kaplan–Meier graphs of a time on mechanical ventilator, b length of stay in the intensive care unit (ICU), and c mortality. Data are presented for the first 28 days after anakinra alignment day. Patients who were no longer mechanically ventilated on alignment day were not included in time on ventilator graph. p values were calculated using log-rank tests. Numbers at risk on each timepoint per group are shown below graphsCC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 19 references

Cited by

Sorted by citations

Related

See all

Metadata

Authors
the RCI-COVID-19 Study Group, Kooistra, E. J., Waalders, N. J. B., Grondman, I., Janssen, N. A. F., de Nooijer, A. H., Netea, M. G., van de Veerdonk, F. L., Ewalds, E., van der Hoeven, J. G., Kox, M., & Pickkers, P.
Affiliations
  • Radboud University Medical Center (NL)
  • University of Bonn (DE)
Corresponding author
Pickkers, Peter
ORCID
Venue
Critical Care
Publisher
Springer Science and Business Media LLC
Published
2020-12
Volume
24
Issue
1
Pages
688-688
ISSN
1364-8535 (ISSN-L)
DOI
10.1186/s13054-020-03364-w
PMC
PMC7726611
OpenAlex
W3112686683
Cited by
119
References
19
Citations by year
2026: 3 · 2025: 3 · 2024: 8 · 2023: 21 · 2022: 34 · 2021: 50
FWCI
3.44
Type
journal article
Language
en
Open access
Licence
Locations
  • Critical Care (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • Amsterdam UMC (VU Amsterdam) - Institutional Repository (publishedVersion, other-oa)
  • Radboud Repository (Radboud University) (submittedVersion, other-oa)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
  • Pure Amsterdam UMC (submittedVersion, cc-by)
  • Data Archiving and Networked Services (DANS) (submittedVersion, other-oa)
Funders
  • H2020 European Research Council (833247)
  • Nederlandse Organisatie voor Wetenschappelijk Onderzoek
  • Radboud Universitair Medisch Centrum
Topics
  • Health Sciences › Medicine › Infectious Diseases › COVID-19 Clinical Research Studies
  • Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Respiratory Support and Mechanisms
  • Health Sciences › Medicine › Critical Care and Intensive Care Medicine › Sepsis Diagnosis and Treatment
Keywords
anakinra, COVID-19 pandemic, hyperinflammation, interleukin-1 receptor antagonist, critically ill patients, mechanical ventilation, cytokines, ferritin, procalcitonin, inflammatory markers, clinical outcomes
MeSH terms
COVID-19, COVID-19 Drug Treatment, Aged, Female, Humans, Male, Middle Aged, Prospective Studies, Cohort Studies, Critical Illness, Receptors, Interleukin-1, Statistics, Nonparametric, Interleukin 1 Receptor Antagonist Protein, Pandemics

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review